Aims To review systematically the published literature on extended-release naltrexone (XR-NTX, Vivitrol ® ), marketed as a once-per-month injection product to treat opioid use disorder. We addressed the following questions: (1) how successful is induction on XR-NTX; (2) what are adherence rates to XR-NTX; and (3) does XR-NTX decrease opioid use? Factors associated with these outcomes as well as overdose rates were examined. Methods We searched PubMed and used Google Scholar for forward citation searches of peer-reviewed papers from January 2006 to June 2017. Studies that included individuals seeking treatment for opioid use disorder who were offered XR-NTX were included. Results We identified and included 34 studies. Pooled estimates showed that XR-NTX induction success was lower in studies that included individuals that required opioid detoxification [62.6%, 95% confidence interval (CI) = 54.5-70.0%] compared with studies that included individuals already detoxified from opioids (85.0%, 95% CI = 78.0-90.1%); 44.2% (95% CI = 33.1-55.9%) of individuals took all scheduled injections of XR-NTX, which were usually six or fewer. Adherence was higher in prospective investigational studies (i.e. studies conducted in a research context according to a study protocol) compared to retrospective studies of medical records taken from routine care (6-month rates: 46.7%, 95% CI = 34.5-59.2% versus 10.5%, 95% CI = 4.6-22.4%, respectively). Compared with referral to treatment, XR-NTX reduced opioid use in adults under criminal justice supervision and when administered to inmates before release. XR-NTX reduced opioid use compared with placebo in Russian adults, but this effect was confounded by differential retention between study groups. XR-NTX showed similar efficacy to buprenorphine when randomization occurred after detoxification, but was inferior to buprenorphine when randomization occurred prior to detoxification. Conclusions Many individuals intending to start extended-release naltrexone (XR-NTX) do not and most who do start XR-NTX discontinue treatment prematurely, two factors that limit its clinical utility significantly. XR-NTX appears to decrease opioid use but there are few experimental demonstrations of this effect.
INTRODUCTION
Opioid misuse and dependence is a significant global disease burden that varies geographically [1] . In the United States, overdose deaths and the prevalence of opioid use disorder (OUD) from prescription opioids, heroin and illicitly manufactured synthetic opioids have increased dramatically in the past two decades [2] [3] [4] . This epidemic has prompted actions to expand funding and access to treatment services [5, 6] , including medication-assisted treatment (MAT) that many individuals could benefit from, though rarely receive [7] . Three MATs are approved by the Food and Drug Administration (FDA) for OUD in the United States [8] . Their therapeutic effects are mediated primarily through the μ-opioid receptor and include the full agonist methadone, the partial agonist buprenorphine and the full antagonist naltrexone [9] . Any licensed provider (e.g. physician, nurse practitioner) can prescribe naltrexone, whereas buprenorphine requires special training and carries limits on the number of patients each provider can treat [10] . Methadone is more regulated and dispensed only by certified opioid treatment programs [11] .
Decades of research show that methadone and buprenorphine can reduce opioid use and increase treatment retention [12, 13] , and both are listed as essential medicines by the World Health Organization (WHO) [14] . In contrast, there is limited evidence that oral naltrexone promotes opioid abstinence and treatment retention, despite being available and approved to treat OUD since 1984. A systematic review of 13 studies involving 1158 participants [15] found no significant differences in these outcomes for participants offered oral naltrexone compared to placebo and to no-medication controls. The authors concluded that the studies did not permit an adequate evaluation of oral naltrexone's effects for OUD treatment.
The inability to properly evaluate oral naltrexone was due to poor adherence-fewer than one-third of participants who began taking oral naltrexone continued to the end of treatment, which averaged 6 months. When participants adhere to oral naltrexone at higher rates, such as those produced by contingency management interventions [16] , the effects on opioid use are significant [17] . However, in the absence of specialized interventions, problems related to adherence reduce the effectiveness of naltrexone. Thus, its use has been limited to highly motivated populations [18, 19] .
To improve adherence and naltrexone's clinical potential for treating OUD, extended-release injectable and surgically implantable formulations have been developed and evaluated in several countries [20] . Whereas oral naltrexone must be taken at least three times per week, one dose of these longer-acting formulations can deliver therapeutic levels of naltrexone that last from 1 to 7 months. The increased duration of exposure to naltrexone in one implantable formulation has been shown to decrease overdose risk associated with poor adherence to oral naltrexone [21] . Unlike methadone and buprenorphine, however, naltrexone is contraindicated for individuals with current physiological dependence on opioids because its use in these individuals can precipitate severe withdrawal [22] . Therefore, it is recommended that individuals be abstinent from all opioids for at least 7-10 days before receiving their first dose.
Multiple longer-acting formulations have been tested [23, 24] , but only one is approved by the FDA for OUD [approved in 2010 and marketed as Vivitrol ® (extended-release naltrexone, referred to hereafter as XR-NTX)] [25, 26] . XR-NTX contains 380 mg naltrexone delivered as an intramuscular gluteal injection and is well tolerated with mild side effects (e.g. headache, injection site soreness) [27, 28] . Dosing occurs monthly and blocks the subjective, reinforcing and physiological effects of opioids [29] . Relative to methadone and buprenorphine, there are a limited number of studies on XR-NTX for OUD. The most recent review of XR-NTX's therapeutic efficacy for OUD from 2013 [26] included five studies, two of which were conference presentations. In recent years, however, many prospective and retrospective studies on XR-NTX for OUD have been completed and published.
In the present review, we provide a systematic and comprehensive update of studies evaluating XR-NTX for OUD and address the following primary questions: (1) how successful is induction on XR-NTX; (2) what are adherence rates to XR-NTX; (3) does XR-NTX decrease opioid use; and (4) what are the factors associated with induction on and adherence to XR-NTX and opioid use during XR-NTX treatment? We also examined reports of overdose deaths, which have been reviewed previously for oral and implantable naltrexone formulations but not XR-NTX.
METHODS
We followed the guidelines of the Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) [30] and pre-registered the protocol in PROSPERO (CRD42016036755).
Search strategy
We performed a systematic review of the literature using PubMed from January 2006 to June 2017. Studies that were written in English, were conducted in humans, contained the word string 'naltrexon*' in the title or abstract, included 'opioid related disorders' as a MeSH heading and were published beginning in 2006 were considered (See Supporting information for full search syntax). We chose this date because it was the year in which the first outpatient randomized controlled trial (RCT) using injectable naltrexone for OUD was published [31] . We reviewed the references of all relevant studies and used Google Scholar for forward citation searching to identify additional studies.
Inclusion criteria
Studies that met the following criteria were included: (1) the study was peer-reviewed; (2) participants were seeking treatment for opioid use or met criteria for opioid abuse, opioid dependence or OUD; (3) one or more injections of XR-NTX were offered; (4) XR-NTX was the FDA-approved formulation (Vivitrol ® ); (5) the study was not exclusively in-patient; and (6) the study reported outcomes or predictors of XR-NTX induction, adherence or its effects on opioid use. We chose to exclude studies using injectable or implantable formulations of naltrexone not approved by the FDA (e.g. Depotrex ® ) to focus our findings on the formulation used currently in practice in the United States, because these other formulations have been reviewed recently [23, 24] and because little new research has been published on their effects. Studies that were exclusively inpatient could be included if they reported induction as an outcome (e.g. in-patient detoxification and induction evaluations). There were no restrictions related to study design, population or comparator (if included).
Outcomes
The primary outcomes were (1) rate of induction on XR-NTX, defined as the percentage of participants enrolled in a study offering XR-NTX who received their first injection; (2) adherence to XR-NTX, defined as the percentage of participants receiving each injection; and (3) opioid use, defined as the percentage of urine samples negative for opioids. Not all studies included in this review used these outcome definitions. Variations and different definitions are noted for individual studies. Overdose outcomes were simple counts and percentages.
Data extraction
We used a standardized template to extract data from each study, which included general information (e.g. year, setting) and methods (e.g. design, duration) and methods and results specific to each outcome (e.g. for induction-if a formal detoxification was included, description of induction protocols, induction success rate, reasons for failures).
Review methods, quality assessments and data synthesis
Study selection was performed independently by two authors. The standardized template was pre-piloted independently by two authors, and the first author extracted all relevant data for the review. Disagreements in study selection and issues related to data extraction were resolved by discussion among the authors. Two authors evaluated quality assessments independently for each study and for each outcome within a study and reached consensus by discussion. The Cochrane Collaboration's tool [32] was used for RCTs, the Downs & Black checklist for nonrandomized studies [33] and the Newcastle-Ottawa quality assessment scale for cohort studies [34] .
Rates of induction on and adherence to XR-NTX were pooled statistically using an inverse variance randomeffects model [35] to account for significant heterogeneity across studies. Post-hoc analyses of subgroups identified during the review process were also performed. Metaanalytical approaches were not pursued for opioid use outcomes, as there were too few studies (≤ 2) that isolated the effects of XR-NTX on opioid use using the same comparator. Throughout the review, we use a structured narrative format to synthesize the literature, organized by research question and study design. In general, prospective study designs were investigational studies conducted in a research context according to a study protocol, whereas retrospective study designs were chart and other medical record reviews taken from routine clinical care settings.
RESULTS

Included studies
A total of 270 studies were assessed for eligibility. We included 34 studies that reported outcomes on XR-NTX induction (n = 17), adherence (n = 24) or opioid use (n = 25). Fifteen studies reported overdose outcomes. While revising the manuscript, two large comparative effectiveness trials [36, 37] of XR-NTX were published and added to this review. Results from the study selection process are shown in Fig. 1 , and general study characteristics are shown in Table 1 .
Quality assessments
Quality ratings are shown in Table 2 . Twelve studies were RCTs, six of which were designed specifically to evaluate XR-NTX versus a control; 12 were non-randomized studies; and six were cohort studies. RCTs were generally of low risk across categories and outcomes. Nearly all RCTs offered XR-NTX as open-label, which introduced potential bias for adherence and opioid use outcomes. Assessment blinding was rarely reported and its impact on bias was unclear. Quality ratings for non-randomized studies varied, with most studies having low external validity, moderate bias and moderate to significant confounding. The cohort studies were well designed and had few poor-quality indicators. One study [48] failed to control for confounding participant factors and definitions of opioid abstinence were unclear in two studies [55, 56] .
Induction on XR-NTX
Prospective studies
Fifteen prospective studies reported outcomes on XR-NTX induction (Table 3) . Five [28, 37, 42, 47, 48] required opioid abstinence at the outset, and one [50] did not require opioid abstinence but recruited recently incarcerated participants who were nearly all abstinent upon release from jail or prison. The nine remaining studies [36, [38] [39] [40] 44, 45, 49, 51, 52] included individuals who were actively using opioids and required detoxification. We identified several procedures for detoxifying and inducting individuals on XR-NTX. One research group [38, 39] used a rapid 7-8-day in-patient procedure, which they later expanded to an out-patient setting [51] . The protocol involved a brief buprenorphine stabilization followed by a washout and gradually increasing doses of oral naltrexone for 3-4 days. A small pilot study [49] evaluated a slightly different rapid 8-day procedure delivered in an out-patient setting that began with 3 days of very low dose oral naltrexone (i.e. < 1 mg) combined with buprenorphine. Thereafter, buprenorphine was stopped and oral naltrexone increased over 4 days. In both rapid induction protocols, withdrawal was managed with non-opioid medications (e.g. clonidine, trazodone, zolpidem). Another procedure [40, 44] occurred in a specialized out-patient employment-based drug treatment center [68] , lasted 1-4 weeks and used a form of contingency management (i.e. employment-based reinforcement). Financial incentives were used to promote opioid abstinence (for participants with recent use) and oral naltrexone adherence. Participants who provided opioidnegative urine samples and/or adhered to staff-observed oral naltrexone doses could earn wages for working in a therapeutic work-place.
Rates of XR-NTX induction ranged from 33 to 72% for studies that included individuals requiring opioid detoxification (Fig. 2) . Overall, studies that targeted individuals requiring detoxification had lower induction rates than studies that did not require detoxification [pooled estimate (62.6%, 95% confidence interval (CI) = 54.5-70.0% versus 85.0%, 95% CI = 78.0-90.1%]. Common reasons for failing to initiate XR-NTX were failing to Study is ongoing. The manuscript reports outcomes through two injections (i.e. 2 months), but adherence to 2nd injection is not reported in this review because investigators were blind to whether injections were XR-NTX or placebo, which could impact adherence [27] . e Some patients remained in treatment longer than 4 months; 4 months used as outcome because data were reported at this time-point for all participants.
f Sample overlaps with that used in [54] . Only outcomes not reported in that study are reported for [57] . One of the three studies was Bisaga et al. [39] . Data were obtained from 150 consecutive admissions, and the total number of participants used from this study is not reported. complete the detoxification (if included), relapse, being lost to follow-up and declining the medication (Supporting information, Table 1 ). One pilot study [45] compared medication initiation rates between individuals requiring detoxification who were randomized to XR-NTX or treatment as usual (i.e. buprenorphine or methadone). Induction on XR-NTX was significantly lower than on buprenorphine or methadone (41.7 versus 100%). A larger trial [36] reported similar findings that induction was significantly lower for participants randomized to receive XR-NTX versus buprenorphine (72.1 versus 94.1%). Among patients who are already detoxified, rates of induction for patients randomized to receive XR-NTX or buprenorphine were similar (88.9 and 91.1%, respectively) [37] .
Retrospective studies
Only one retrospective study reported XR-NTX induction outcomes [58] . Data were gathered from 7687 privately insured, opioid-dependent individuals receiving treatment in residential programs. Just 8% of patients were recommended for XR-NTX. Among those recommended for XR-NTX, fewer than one-third (28.1%; 168 of 598) received their first injection. For unknown reasons, many participants (31.6%) changed their minds about taking XR-NTX. Others were unable to pay for the medication (20.7%, due usually to insurance denial), discharged early (28.1%) or left against medical advice (15.6%). It is stated that analyses were intent-to-treat, however, the Consolidated Standards of Reporting Trials (CONSORT) figure suggests analyses were per-protocol.
Factors associated with induction
Four studies [39, 40, 42, 51] investigated experimentally whether adjunctive medication, detox-type or induction contingencies and setting impacted XR-NTX induction, and four studies [39, 44, 51, 64] examined baseline predictors of XR-NTX induction. Adding dronabinol (a cannabinoid-1 partial agonist) to an 8-day in-patient rapid detox did not improve induction rates significantly compared to placebo (66 versus 55%). Although statistical tests were not reported, participants receiving employment-based contingency management for adherence to XR-NTX had higher induction rates than those whose adherence was not contingent upon accepting XR-NTX (100 versus 84.2%) [40] . Only one study [51] evaluated different induction procedures experimentally and showed that individuals undergoing a 7-day outpatient naltrexone-assisted detox followed by XR-NTX on day 8 were nearly three times more likely to be inducted than those receiving a 7-day out-patient buprenorphineassisted detox followed by a 7-day washout period (XR-NTX on day 15). A small pilot study [42] among adult inmates showed that those randomized to receive XR-NTX prior to release had higher rates of induction than those referred to the community to be inducted after release. This finding was also observed in one prospective natural experiment study [48] .
An analysis of 29 patient demographics receiving a 7-day rapid in-patient detox [64] found that only two measures were associated with success. Patients who were older and used fewer opioids daily were more likely to complete the detox. Among participants receiving out-patient detox and XR-NTX induction, success was higher for prescription opioid users than heroin users but did not differ by route of opioid use or daily opioid use amount [51] . Within a sample of opioid users with marijuana use histories, pre-enrollment marijuana use predicted successful induction [39] . Finally, in an out-patient contingency management procedure, participants who had recently completed a long-term detox (≥ 21 days) and who were not on parole or probation were more likely to complete the induction than those who completed a shorter-term detox (< 21 days) or who were on parole or probation [44] .
Adherence to XR-NTX
Prospective studies
Sixteen prospective studies reported outcomes on adherence to XR-NTX [27, 28, [36] [37] [38] [39] [40] [41] [42] [43] [45] [46] [47] [48] 51, 52] (Table 4) , which was usually evaluated for six injections or fewer (87.5%; 13 of 16 studies). Adherence rates varied but generally decreased over time. The highest drop-off in adherence rates occurred early in treatment, usually between participants' first and second injection (Fig. 3) . Rates of perfect adherence to 6 months among participants who started XR-NTX ranged from 15 to 74% (pooled estimate = 46.7%, 95% CI = 34.5-59.2%). Longer adherence rates (13 and 19 months) were reported in a study from Russia [46] , which showed that individuals who completed 6 months of XR-NTX or placebo treatment in a previous study [27] adhered continuously the following year at rates of 58.2 and 68.1%, respectively (31.0 and 25.8% of the original samples, respectively). A long-term United States study with health-care professionals found that 12-and 24-month adherence rates were 55.3 and 36.8% [41] . The only placebocontrolled study [27] showed that adherence was higher to XR-NTX than placebo (57.9 versus 41.9%). A recent pilot study [45] compared adherence to XR-NTX and treatment as usual (buprenorphine/methadone). Rates of adherence were higher among those who started XR-NTX (five of five: 100%) than buprenorphine or methadone (six of 12: 50%). In much larger trials, adherence rates for individuals who start XR-NTX have been shown recently to be similar to those for buprenorphine to 3 [37] (XR-NTX: 78.9% versus buprenorphine: 68.1%) and 6 months [36] (XR-NTX: 47.1% versus buprenorphine: 42.6%).
Retrospective studies
Seven retrospective studies reported adherence outcomes [22, 53, 54, [59] [60] [61] [62] (Table 4) . Observation periods were generally approximately 6 months long. The decline in adherence rates varied over time, but were fewer than 50% by the third injection (pooled estimate = 46.3%, 95% CI = 27.0-66.7%; Fig. 3 ). Fewer than 10% of participants adhered to XR-NTX through their sixth Figure 2 Average rates of extended-release naltrexone (XR-NTX) induction for 15 prospective studies. Numbers above each bar refer to the number of participants for each study (or group) who received their first injection of XR-NTX and the number of participants who were enrolled to receive XR-NTX. *These studies did not exclude individuals who were using opioids actively but more than 90% of participants in these studies did not require opioid detoxification. †Induction rates significantly different between groups. See 'Factors associated with induction' section for more detailed description of detox procedures. ‡Statistical comparisons not reported for induction outcomes. PRE and POST refer to whether induction occurred in jail before release (PRE) or in the community after release (POST) injection (pooled estimate = 10.5%, 95% CI = 4.6-22.4%). A follow-up study [62] of respondents who enrolled in an XR-NTX clinical study [51] showed that 12% were in XR-NTX treatment at the time of the survey (21 months on average after study completion) and 26% received at least one XR-NTX injection after the intervention ended.
One study [53] compared XR-NTX adherence to oral NTX, buprenorphine and methadone among a sample of privately insured patients receiving treatment from 2005 to 2009 (prior to XR-NTX's FDA approval for OUD). A higher percentage of patients receiving XR-NTX (21%) had medication possession ratios (i.e. ratio of days' supply of the medication to total days in the observation period) ≥ 0.8 compared to patients receiving oral NTX (8%). Patients receiving methadone (29%) did not differ from those receiving XR-NTX on this outcome, but patients receiving buprenorphine had higher rates (34%). There were no group differences based on mean number of persistent days with medication. Among adolescents, one study showed that rates of adherence to XR-NTX and buprenorphine were similar throughout 6 months of treatment [61] .
Factors associated with adherence
Five studies evaluated methods experimentally to improve XR-NTX adherence (Supporting information, Figure 1 ). Compared to placebo, adding dronabinol to XR-NTX treatment had no significant effect on adherence [39] , whereas adding memantine produced significantly lower treatment retention and adherence [38] . In contrast, employment- Six injections were offered but adherence for the 4th and 5th injections was not reported, and therefore means and SDs could not be calculated for all six injections. Outcomes reported here are for the first three injections. Subsample of participants (34%) from Sullivan et al. [51] who completed a follow-up survey after the parent trial. p Average follow-up time since study completion was 21 months. q SD could not be calculated. Range, which was reported, is shown instead. These numbers refer only to the subsample of participants who completed the follow-up survey and received XR-NTX after the parent trial ended.
based reinforcement for XR-NTX adherence promoted significantly higher rates of adherence. Six-month adherence rates for participants receiving employmentbased reinforcement for XR-NTX adherence (73.7%) were tied, with those seen in US health-care professionals the highest of any study or subgroup. Among participants who initiated XR-NTX, those who had received naltrexone-assisted detox received their second injection of XR-NTX immediately (89.1%) at similar rates to those who received a buprenorphine-assisted detox followed by a 7-day washout period (82.4%) [51] . Finally, incarcerated participants who initiated XR-NTX prior to release had higher adherence than those who were referred to XR-NTX treatment in the community, although this effect disappeared over time [42] .
Eight studies [38, 39, 43, 51, 52, 54, 57, 60] reported whether a variety of participant factors (e.g. demographics, drug use) were associated with XR-NTX adherence (Supporting information, Table 2 ). Some variables were related to adherence, but many of the associations were inconsistent throughout studies or reported only by one study. Thirteen studies [22, 27, 28, [36] [37] [38] 40, 41, 43, 46, 47, 52, 62] provided some information on reasons for non-adherence after beginning XR-NTX, which included losing contact with participants (e.g. treatment dropout, loss to follow-up, incarceration), adverse events and other personal reasons (see Supporting information, Table 1 ).
XR-NTX and opioid use
The duration of XR-NTX (1-24 months), opioid use outcome measures and methods of handling missing data varied considerably across the prospective studies. Given this heterogeneity, detailed findings are reported for individual studies in Table 5 . Sixteen prospective studies offered at least one injection of XR-NTX and reported opioid use outcomes. 
Prospective studies that did not isolate experimentally the effects of XR-NTX on opioid use
Bisaga [38] 2014 Weekly % who used opiates Unclear % who used opiates did not differ between the memantine and placebo groups. Actual % for each group not reported. 64% used opiates once or more 1 month after 1st injection. 43% used opiates 1 month after 2nd injection (Continues) 
Method(s) of handling missing outcomes Findings
Bisaga [39] 2015 Weekly % who used opiates Unclear % who used opiates did not differ between the dronabinol and placebo groups. Actual % for each group not reported. 63% used opioids at least once during trial
DeFulio [40] 2012 % of urine samples negative for opiates
Missing-positive and missing-missing There was no difference on opiate abstinence between the incentives (71.6%) and control group (65.3%) a Earley [41] 2017 % of participants who tested positive for opioids, % of participants who relapsed to opioids 
Prospective studies that isolated experimentally the effects of XR-NTX on opioid use (i.e. RCTs)
Six studies evaluated the effects of XR-NTX on opioid use. Two pilot studies [45, 47] and one larger study [28] compared XR-NTX to treatment referral controls, one study [27] compared XR-NTX to placebo and two studies compared XR-NTX to buprenorphine with randomization occurring before [36] or after [37] opioid detoxification was completed (Table 5 ). Two of the three studies that compared XR-NTX to treatment referral controls found that XR-NTX produced superior opioid use outcomes (one study did not test for group differences). The pivotal placebo-controlled study [27] also reported better opioid use outcomes but did not demonstrate an effect of XR-NTX on opioid use independent of treatment retention. When randomization occurred after opioid detoxification, XR-NTX was found to be non-inferior to buprenorphine [37] . However, when randomization to XR-NTX and buprenorphine took place prior to opioid detoxification, participants assigned to receive buprenorphine had significantly better opioid use outcomes, an effect that was attributed to XR-NTX's induction hurdle and subsequent relapse among induction failures [36] .
Prospective studies that did not isolate experimentally the effects of XR-NTX on opioid use
Ten studies offered open-label use of XR-NTX using no controlled comparator with [38] [39] [40] 42, 51] or without [41, 43, 46, 49, 52] randomized evaluations of induction protocols or adjunctive treatments (Table 5 ).
Retrospective studies
Six retrospective studies (Table 5) reported outcomes on opioid use, three of which compared the effects of XR-NTX to other MATs or no medication controls [55, 56, 61] . Among parolees and probationers, opioid use outcomes observed in XR-NTX recipients were similar to those receiving oral naltrexone but better than both buprenorphine and psychosocial treatment only [55] . No differences in opioid use were observed between these medications in a similar study using a community sample [56] or among adolescents receiving XR-NTX or buprenorphine [61] . Three other studies, one in adolescents [22] , one in dually diagnosed individuals [59] and one in individuals who had completed an XR-NTX clinical study [62] reported outcomes of receiving XR-NTX with no control, to a pre-XR-NTX period or as a function of past XR-NTX adherence (see Table 5 ).
Factors associated with XR-NTX and opioid use
Eight studies reported correlational or experimental analyses of predictors of the effect of XR-NTX on opioid use. A secondary analysis [65] of the pivotal placebocontrolled study [27] showed that none of the 25 baseline factors predicted a positive clinical response to XR-NTX. Two secondary analyses [63, 66] of a large US study comparing XR-NTX to treatment referral [28] found that XR-NTX induction setting interacted with opioid relapse and that of 36 baseline factors only alcohol use to intoxication moderated the treatment effect. Specifically, because relapse was higher among patients who received XR-NTX during a short-term in-patient stay, its protective effects were greater than those who received XR-NTX during long-term in-patient stays and in out-patient settings. However, the effect of induction setting was only significant in the short term (5 weeks; not significant at 26 weeks). XR-NTX was more likely to prevent relapse in participants who did not report drinking to intoxication 30 days before randomization. Two recent studies showed that education level and subscales on the Addiction Severity Index [52] and daily opioid amount, type of opioid use (heroin versus prescription opioids) and route of administration [51] were not predictive of opioid urine outcomes. Further, adding dronabinol [39] , memantine [38] or employment-based reinforcement for XR-NTX adherence [40] did not improve opioid use outcomes significantly.
XR-NTX and overdose
Of the 22 studies that reported original opioid use outcomes (i.e. not secondary analyses), 12 prospective and three retrospective studies reported data on overdose associated with XR-NTX (see Supporting information, Table 3 ). Methods of monitoring overdose outcomes varied. One small pilot study audited the National Death Index [47] , whereas the majority recorded adverse events at study visits or did not provide details on how overdose events were determined. In 60% (nine of 15) of the studies, there were no reported overdose events among individuals assigned to receive XR-NTX. In the six studies where overdoses (non-fatal and/or fatal) were reported, non-fatal overdose death rates were 3.5% (two of 57), 4.0% (one of 25) and 5.3% (15 of 283); fatal overdose death rates were 0.7% (one of 150), 0.7% (two of 283), 1.2% (two of 171) and 4.5% (three of 67). No studies were powered to detect significant differences in overdose between XR-NTX and any comparators.
DISCUSSION
Since a previous review in 2013 [26] , 29 studies have been published that report original investigations of XR-NTX in populations with OUD. In this systematic review, we present an up-to-date and comprehensive synthesis of the published literature on XR-NTX to treat OUD. We examined whether XR-NTX decreases opioid use, but also reported two outcomes critical to its success-starting and continuing to take the medication. We also explored what patient and intervention factors predicted greater induction, adherence and treatment response, and examined rates of overdose in published studies. There was considerable heterogeneity in the study designs, outcomes and findings, but we offer the following general conclusions and recommendations for future research.
Induction on XR-NTX
Most participants started XR-NTX in studies focusing upon individuals who were already detoxified from opioids; however, for those requiring detoxification, approximately 40% did not start XR-NTX. This result suggests that XR-NTX induction is likely to be high among patients who achieve initial opioid abstinence. XR-NTX may be the most appealing medication option for these individuals, who may be reluctant to start treatment with methadone or buprenorphine. Although detoxified patients had more success starting XR-NTX, evidence of this outside the context of investigational studies, which were usually conducted in academic medical settings, is limited. Only one study [58] reported induction outcomes among detoxified patients in routine care, in which fewer than one-third recommended for XR-NTX started it. Practical issues not inherent in investigational studies may explain this discrepancy and pose additional constraints on starting XR-NTX, and include the timing of medication ordering, storage and delivery before discharge; covering the high cost of XR-NTX and negotiating insurance coverage; and ensuring that patients will have access to continuing XR-NTX treatment after initiation [70] .
Few individuals seeking treatment will have achieved the 7-10 days of opioid abstinence to start XR-NTX recommended in the manufacturer's medication packet insert. There is no agreed-upon detoxification and XR-NTX induction protocol, but rapid week-long procedures that involve brief buprenorphine and increasing low-dose naltrexone accompanied by non-opioid medications to manage withdrawal discomfort [38, 39, 49] have been the most commonly evaluated approaches. These methods may be superior to detoxification with buprenorphine alone [51] and could be implemented in out-patient settings, where most patients receive treatment [71] , but may require significant changes to the out-patient treatment of OUD (e.g. use a compounding pharmacy, open 7 days per week). A major advantage of XR-NTX is that it is not regulated like methadone or buprenorphine, and providers do not have to complete specialized waivers to prescribe it. Critical questions are whether providers-some of whom may have limited or no training in treating OUD-will be able to manage patients easily and safely through the induction protocols, be willing to treat these individuals and have appropriate training and support to feel comfortable administering the injections [72] .
The induction hurdle for individuals requiring detoxification limits the clinical utility of XR-NTX treatment significantly. Future research should investigate novel methods experimentally to detoxify and induct patients on XR-NTX rapidly with greater success, and assessments of the feasibility and induction rate of these protocols in routine care will be needed. In addition, studies should continue to explore patient-level factors that may predict starting XR-NTX successfully. Some behaviors characteristic of less severe opioid use (i.e. using less [64] , using primarily prescription opioids [51] , being able to complete a long-term detox [44] ) may be associated with better outcomes, but these findings need to be replicated.
Adherence to XR-NTX
Adherence rates decreased over time, with 47% of participants who started XR-NTX still adhering at the latest time-point, which averaged less than 6 months. Prospective investigational studies conducted in a research context according to study protocols reported much higher adherence rates over time compared to retrospective medical record review studies taken from routine clinical care settings. The reasons for this large divergence are unclear, but may include differences between samples owing to study exclusion criteria [73, 74] and a host of procedural differences between investigational studies and routine clinical care (e.g. study compensation, medication cost, follow-up efforts, expertise and familiarity with XR-NTX, contact with health-care staff) [75] . The observed difference in adherence between these two types of studies should be interpreted cautiously, however. The comparison was not controlled, and there were just four retrospective studies included.
We chose to report adherence rates based on individuals who initiated XR-NTX treatment and received their first injection. An alternative approach in which XR-NTX induction failures are included produces considerably lower adherence rates. Twelve prospective trials reported outcomes for both induction and adherence [28, [36] [37] [38] [39] [40] 42, 45, 47, 48, 51, 52] . In these studies, pooled adherence estimates at the last time-point, which averaged 4 months, was 59.0% (95% CI = 46.3-70.6%) among those who initiated XR-NTX but decreased to 41.2% (95% CI = 31.9-51.3%) when using an intentto-treat approach among all individuals intending to start XR-NTX.
Offering incentives for accepting XR-NTX was the only intervention that increased long-term adherence [40] . Despite nearly tripling 6-month adherence to XR-NTX, this intervention had only a small effect on reducing opiate use and is unlikely to be adopted in most treatment settings.
There may be patient characteristics that clinicians can identify to predict who will remain engaged in long-term XR-NTX treatment, but none were particularly robust and replicated across studies.
The evidence to evaluate XR-NTX adherence versus buprenorphine and methadone was inconsistent, with studies showing lower, similar and higher XR-NTX adherence [36, 37, 45, 53, 61] . Two recent comparative effectiveness trials [36, 37] suggest that once initiated, rates of adherence to XR-NTX and buprenorphine are similar. However, in the Norwegian trial, buprenorphine was given daily in a controlled environment, which is not the standard delivery method in other countries (e.g. United States), and may have imposed additional barriers to adherence. Although the need to improve treatment retention is not unique to XR-NTX, the resources needed to detoxify completely and induct individuals on XR-NTX are substantial and would be required again after a relapse to resume XR-NTX, an issue not faced by buprenorphine or methadone treatment.
Because the effects of XR-NTX on opioid use have been shown not to persist once discontinued [28] , future research should include longer measures of adherence, particularly in real-world settings. An industry-sponsored multi-center patient registry study of XR-NTX for OUD involving more than 400 patients was completed, but the results have not been published (NCT01422837). Even with the improved long-acting formulation, most patients starting XR-NTX will need additional support and interventions to promote continued adherence. Researchers should evaluate innovative pharmacotherapies and behavioral interventions to keep patients engaged in XR-NTX treatment and identify the characteristics of patients who remain on XR-NTX.
XR-NTX and opioid use
We documented an increase in the number of published studies on XR-NTX for OUD in the past several years that show XR-NTX can decrease opioid use. However, of the 22 investigational studies that reported opioid use outcomes in this review, only six were randomized studies that isolated the effects of XR-NTX, and two of these were small pilot studies. The original pivotal study, conducted in Russia and published in 2011 [27] , showed that XR-NTX increased treatment retention relative to placebo. However, its effect on opioid abstinence was not demonstrated independently because urine sample collection rates differed between groups and the only analysis reported assumed missing samples were positive for opioids. In contrast, a 2016 US study among adults involved in the criminal justice system [28] provided rigorous evidence that XR-NTX reduces opioid use relative to a treatment referral condition.
The recent randomized trials in Norway [37] and the United States [36] are the first to compare the relative effectiveness of XR-NTX to buprenorphine, a gold-standard OUD treatment. The Norwegian trial was brief (3 months), buprenorphine dosing occurred in a controlled environment and the buprenorphine dose was low (11.2 mg). The US trial recruited participants from in-patient detoxification centers, which may have favored XR-NTX induction and contributed to the high induction success (72%; the highest among studies for individuals requiring a detoxification). These limitations notwithstanding, the trials showed that XR-NTX and buprenorphine can produce similar short-term opioid outcomes. Critically, this finding was only true when considering individuals who had completed an opioid detoxification successfully. When induction failures (who typically progressed to relapse) were included, XR-NTX was less effective than buprenorphine in improving opioid use outcomes. This occurred despite the very high induction success rates in this study. As with XR-NTX induction and adherence, more work should identify patient factors associated with a positive response to XR-NTX's effects on opioid use.
XR-NTX and overdose
The number of participants experiencing overdose in the reviewed studies was low, but most studies did not report clearly how overdose events were measured, particularly among participants who were lost to follow-up. The predominant method was to collect adverse event information at weekly or monthly study visits. Given the high dropout rates observed in the reviewed studies and the known overdose risks of stopping agonist treatment [76] , it is critical that future studies and real-world evaluations evaluate and report fatal and non-fatal overdoses more rigorously. The extent to which XR-NTX induction failures may contribute to overdose risk is also unknown and requires further study.
CONCLUSION
XR-NTX could play an important role in curbing the opioid epidemic, but several issues and concerns exist regarding its efficacy and effectiveness in real-world settings. Many individuals intending to start XR-NTX do not, and most who do start XR-NTX discontinue treatment prematurely. XR-NTX appears to decrease opioid use but there are few experimental demonstrations of this effect in the literature. The barriers faced in completing XR-NTX induction limit its clinical utility and impact significantly when compared to buprenorphine. Future work should develop methods of successfully detoxifying and inducting individuals on XR-NTX, design interventions and treatment approaches to increase long-term adherence, and evaluate overdose risks associated with XR-NTX treatment more comprehensively.
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